Amarin (NASDAQ:AMRN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Amarin (NASDAQ:AMRN) in a research report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Amarin Stock Up 4.7 %

Shares of Amarin stock opened at $0.55 on Friday. The firm has a market cap of $225.87 million, a PE ratio of -6.11 and a beta of 1.82. Amarin has a fifty-two week low of $0.43 and a fifty-two week high of $1.37. The business’s fifty day moving average is $0.51 and its two-hundred day moving average is $0.60.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. The company had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $43.82 million. During the same quarter in the previous year, the company earned ($0.05) earnings per share. Equities research analysts anticipate that Amarin will post -0.14 EPS for the current year.

Institutional Investors Weigh In On Amarin

Institutional investors have recently added to or reduced their stakes in the company. Algert Global LLC acquired a new position in shares of Amarin in the 2nd quarter valued at about $34,000. China Universal Asset Management Co. Ltd. raised its holdings in Amarin by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 29,992 shares during the period. Kornitzer Capital Management Inc. KS lifted its position in Amarin by 80.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 42,700 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Amarin by 8.8% during the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock worth $816,000 after buying an additional 104,939 shares during the period. Hedge funds and other institutional investors own 22.25% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.